_640x250.jpg)
Who we are
Matisse Pharmaceuticals BV is a biopharmaceutical clinical stage company dedicated to develop a product portfolio of safe and innovative therapies for disease indications characterized by elevated levels of cell free cytotoxic histones, such as in sepsis and septic shock.
Strategy
The strategy of Matisse Pharmaceuticals is to maximize the value of its novel treatments by advancing the preclinical and clinical development in the fastest, most efficient and cost-effective way possible. The drug development program is managed by a seasoned in-house project team and executed through a combination of in-house and outsourced development activities.
History
Matisse Pharmaceuticals BV was founded in 2014 with the main objective to develop the therapeutic product M6229 for the treatment of sepsis. Matisse Pharmaceuticals is based at the Brightlands Chemelot Campus in Geleen, The Netherlands.